Senseonics Holdings announced that it has signed a collaboration agreement with Diasend that will allow clinical review of patients’ CGM data from the Eversense Continuous Glucose Monitoring (CGM) System using the diasend Clinic and diasend Personal solutions.
Under this agreement, the two companies will work together to enable clinicians and patients to utilize the diasend® solution to review past Eversense CGM data along with insulin pump and activity tracker data.
Senseonics is developing Eversense as a reliable, long-term implantable CGM system to continually and accurately measure glucose levels in people with diabetes for a period of up to 90 days, while the diasend solutions allow users to review glucose reports in familiar and unified formats.
The companies are collaborating to integrate Eversense CGM system with the diasend® solutions, thereby allowing clinicians and patients to access 90 days of continuous glucose data from a single CGM sensor to aid in optimizing therapy regimens.
"We believe that turning data from CGM and or pump devices into actionable data is extremely important to users," said Dr. Tim Goodnow, CEO and President of Senseonics.
"Our aim with the Eversense CGM system is to help people with diabetes spend less time managing their devices and more time managing their diabetes. In our clinical trials we have observed the Eversense sensor to last up to 90 days, the smart transmitter is removable and can provide on-body vibe alerts and the mobile application provides real-time glucose readings and alerts.
"We have also incorporated easy to understand pre-formatted glucose reports so users can see past data and trends directly on the application. Senseonics is extremely pleased to be working with a partner as valuable as Diasend, a company that is already well-known and trusted by the diabetes community, to allow users to have access to additional historical data and a more comprehensive data management solution."
Both companies expect to initially target the European market for the integrated Eversense and diasend® solution.
Senseonics Holdings is a medical technology company focused on the design, development and commercialization of a long-term, implantable continuous glucose monitoring (CGM) system to improve the lives of people with diabetes by enhancing their ability to manage their disease with relative ease and accuracy.